Search

Rishi Rakhit

from Berkeley, CA
Age ~47
Get Report
Connected to:
Esha Rakhit, 37Marsha Rakhlin, 61Aleksandr Y Rakhmanov, 49Bakhodir Rakhmanov, 51Fuad Rakhman, 47Lev A Rakhman, 107Manorama A Rakhmanov, 64Nataliya V Rakhmanina, 41Natella Z Rakhmanova, 42Evelin B Rakhmestryuk, 45

Rishi Rakhit Phones & Addresses

  • Berkeley, CA
  • San Francisco, CA
  • Menlo Park, CA

Work

Company: Mitokinin Nov 2018 to Apr 2019 Position: Senior scientist

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Toronto 2003 to 2008 Specialities: Biochemistry

Skills

Cell Biology • Molecular Biology • Biochemistry • Western Blotting • Cell Culture • Pcr • Molecular Cloning • Microscopy • Protein Expression • Protein Purification

Industries

Higher Education

Resumes

Resumes

Rishi Rakhit Photo 1

Director, Translational Medicine

View page
Location:
Menlo Park, CA
Industry:
Higher Education
Work:
Mitokinin Nov 2018 - Apr 2019
Senior Scientist
Mitokinin Nov 2018 - Apr 2019
Director, Translational Medicine
Achaogen Feb 2018 - Sep 2018
Scientist, Project Team Lead
Denali Therapeutics May 2016 - Feb 2018
Scientist
Stanford University Apr 2014 - Feb 2016
Research Associate
Education:
University of Toronto 2003 - 2008
Doctorates, Doctor of Philosophy, Biochemistry Pickering High School, Ajax
Stanford University
University of Toronto
Skills:
Cell Biology
Molecular Biology
Biochemistry
Western Blotting
Cell Culture
Pcr
Molecular Cloning
Microscopy
Protein Expression
Protein Purification

Publications

Us Patents

Antibodies To Ttr And Methods Of Use

View page
US Patent:
20140056904, Feb 27, 2014
Filed:
Aug 23, 2013
Appl. No.:
13/974761
Inventors:
- Toronto, CA
Rishi Rakhit - Menlo Park CA, US
Anita Antoinette Bugyei-Twum - Scarborough, CA
Assignee:
University Health Network - Toronto
International Classification:
C07K 16/26
C07K 14/575
G01N 33/74
US Classification:
4241391, 4352872, 435 696, 435 792, 5303879, 5303873, 530328, 530300, 536 235, 4241851
Abstract:
The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.

Anti-Trem2 Antibodies And Methods Of Use Thereof

View page
US Patent:
20200277373, Sep 3, 2020
Filed:
Sep 14, 2018
Appl. No.:
16/646536
Inventors:
- South San Francisco CA, US
Gilbert Di Paolo - South San Francisco CA, US
Rui Hao - South San Francisco CA, US
Joseph W. Lewcock - South San Francisco CA, US
Nathan Moerke - South San Francisco CA, US
Alicia A. Nugent - South San Francisco CA, US
Rishi Rakhit - South San Francisco CA, US
Ju Shi - South San Francisco CA, US
Rinkan Shukla - South San Francisco CA, US
Ankita Srivastava - South San Francisco CA, US
Bettina Van Lengerich - South San Francisco CA, US
Yin Zhang - South San Francisco CA, US
Assignee:
Denali Therapeutics Inc. - South San Francisco CA
International Classification:
C07K 16/28
A61P 25/28
C07K 16/40
Abstract:
In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody increases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody decreases levels of sTREM2. In some embodiments, the antibody enhances TREM2 activity. In some embodiments, the antibody inhibits TREM2 activity.

Anti-Tau Antibodies And Methods Of Use Thereof

View page
US Patent:
20200216522, Jul 9, 2020
Filed:
Aug 16, 2019
Appl. No.:
16/543367
Inventors:
- South San Francisco CA, US
Mark S. Dennis - South San Francisco CA, US
Lesley Ann Kane - South San Francisco CA, US
Do Jin Kim - South San Francisco CA, US
Joseph W. Lewcock - South San Francisco CA, US
Suresh Poda - South San Francisco CA, US
Rishi Rakhit - South San Francisco CA, US
Rinkan Shukla - South San Francisco CA, US
Adam P. Silverman - South San Francisco CA, US
Assignee:
Denali Therapeutics Inc. - South San Francisco CA
International Classification:
C07K 16/18
A61P 25/28
Abstract:
In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.

Antibodies To Ttr And Methods Of Use

View page
US Patent:
20190195896, Jun 27, 2019
Filed:
Nov 23, 2018
Appl. No.:
16/198965
Inventors:
- Toronto, CA
Rishi Rakhit - Menlo Park CA, US
Anita Antoinette Bugyei-Twum - Scarborough, CA
International Classification:
G01N 33/78
C07K 16/26
C07K 14/47
C07K 16/18
Abstract:
The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.

Methods And Compositions To Treat And Detect Misfolded-Sod1 Mediated Diseases

View page
US Patent:
20180079825, Mar 22, 2018
Filed:
Mar 31, 2017
Appl. No.:
15/476440
Inventors:
- TORONTO, CA
AVIJIT CHAKRABARTTY - VAUGHAN, CA
RISHI RAKHIT - SAN FRANCISCO CA, US
JOACHIM BERNHARD OSTERMANN - EDMONTON, CA
International Classification:
C07K 16/40
G01N 33/68
G01N 33/573
C12N 9/02
Abstract:
The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.

Antibodies To Ttr And Methods Of Use

View page
US Patent:
20170089929, Mar 30, 2017
Filed:
Dec 9, 2016
Appl. No.:
15/373657
Inventors:
- Toronto, CA
Rishi Rakhit - Menlo Park CA, US
Anita Antoinette Bugyei-Twum - Scarborough, CA
International Classification:
G01N 33/78
C07K 14/47
C07K 16/18
Abstract:
The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.

Light-Inducible System For Regulating Protein Stability

View page
US Patent:
20140249295, Sep 4, 2014
Filed:
Feb 28, 2014
Appl. No.:
14/194052
Inventors:
- Stanford CA, US
Rishi Rakhit - Menlo Park CA, US
Thomas J. Wandless - Menlo Park CA, US
Assignee:
The Board of Trustees Of The Leland Stanford Junior University - Stanford CA
International Classification:
C07K 14/00
US Classification:
530350, 536 234, 435 697, 435357
Abstract:
Disclosed herein are a light-inducible system and method for rapidly and reversibly modulating protein stability and function. This system and method employs conditionally stable protein domains that regulate the degradation of a fusion protein depending upon the presence or absence of a particular light source.
Control profile
Rishi Rakhit from Berkeley, CA, age ~47 Get Report